Akebia Therapeutics (NQ: AKBA )
1.550
+0.030
(+1.97%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
All News about Akebia Therapeutics
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_150.jpeg?width=720)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2021/movers_image_7043.jpeg)
![](https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template.jpg)
Akebia Therapeutics, inc (AKBA) Q3 2021 Earnings Call Transcript
November 09, 2021
Via The Motley Fool
Topics
Earnings
Exposures
Financial
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_1558.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/yesterdays_movers_260.png)
![](https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template.jpg)
Akebia Therapeutics, inc (AKBA) Q2 2021 Earnings Call Transcript
August 05, 2021
Via The Motley Fool
Topics
Earnings
Exposures
Financial
![](https://g.foolcdn.com/editorial/images/637623/dialysis.jpg)
![](https://mms.businesswire.com/media/20210727006169/en/827144/5/Schall-Firm-Logo-640x360.jpg)
![](https://mms.businesswire.com/media/20210726005689/en/805463/5/business_Wire_Robbins_LLP.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/sites/all/themes/bz2/images/bz-icon.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/sites/all/themes/bz2/images/bz-icon.png)
![](https://www.newmediawire.com/media/sites/270/images/social-image.jpg)
Via NewMediaWire
Topics
Lawsuit
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/sites/all/themes/bz2/images/bz-icon.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_581.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/sites/all/themes/bz2/images/bz-icon.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_518.png)
Akebia Therapeutics Stock Jumps as FDA Accepts Vadadustat US Application in CKD-Related Anemia
June 01, 2021
Via Benzinga
Exposures
Product Safety
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/sites/all/themes/bz2/images/bz-icon.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/sites/all/themes/bz2/images/bz-icon.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/nerve-cell-2213009_1920_25.jpg)
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.